[1128] Increased Expression of HIF-1α in Invasive Endocervical Adenocarcinoma.

Dongping Shi, Quratulain Ahmed, Sudeshna Bandyopadhyay, Haitham Arabi, Yaser Hussein, Bassam Albashiti, Tarek Jazaerly, Zaid Al-Wahab, Sumit Yadam, Rouba Ali-Fehmi. Wayne State University, Detroit, MI; Detroit Medical Center, Detroit, MI

Background: Tumor hypoxia is a well-known microenvironmental factor that causes cancer progression and resistance to treatment. The proposed mechanisms are complex but believed to involve mediation through transcriptional gene activation by the hypoxia-inducible factors (HIFs). HIFs in turn are known to upregulate GLUT receptors which are also known to be associated with tumor progression. Our objective was to characterize the expression of HIF-1α, GLUT-1 and Ki-67 in in-situ (AIS) and invasive endocervical adenocarcinoma.
Design: Seventy-nine consecutive patients diagnosed with AIS and invasive endocervical adenocarcinoma in our institute from 1994 to 2010 were included in the study. Of these 43 were AIS and 36 were invasive adenocarcinoma. Tissue microarrays were constructed and immunohistochemical staining was performed using antibodies against HIF-1α, GLUT-1 and Ki-67. Semi-quantitative scoring of immunoreactivity was based on intensity and percentage of tumor staining and grouped into low and high expression for statistical analysis.
Results: A significantly larger proportion of cases within the invasive cancer group showed high expression of all three markers (HIF-1α, GLUT-1 and Ki-67) when compared to the in situ cohort.

Invasive Carcinoma N=43High24(57%)15(68%)27(63%)
Adenocarcinoma In Situ N=36High12(33%)2(6%)10(28%)

aSome cases missing due to processing
Conclusions: The high expression of hypoxic markers including HIF-1α and GLUT-1 in invasive endocervical adenocarcinoma compared to AIS may provide insight into the pathway of tumor progression from the pre-invasive into the invasive phase of the endocervical adenocarcinoma. These data suggest that HIF-1α-mediated pathway may be a candidate for a targeted therapy.
Category: Gynecologic & Obstetrics

Tuesday, March 1, 2011 9:30 AM

Poster Session III # 217, Tuesday Morning


Close Window